| Stereochemistry | RACEMIC |
| Molecular Formula | C6H8N2O2 |
| Molecular Weight | 140.1399 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1CN2C(CCC2=O)N1
InChI
InChIKey=XTXXOHPHLNROBN-UHFFFAOYSA-N
InChI=1S/C6H8N2O2/c9-5-3-8-4(7-5)1-2-6(8)10/h4H,1-3H2,(H,7,9)
Dimiracetam is a nootropic drug of the racetam family. Dimiracetam inhibited the NMDA-induced increase of [3H]D-Asp release from hippocampal synaptosomes. The increased potency and longer duration of action of dimiracetam, together with the potential cognition enhancing property makes it a very promising and safe for the treatment of neuropathic pain conditions for which there are very limited therapeutic options. Dimiracetam is in Phase II clinical trials for the treatment of HIV-associated pain and in phase I clinical trials for the treatment of osteoarthritis pain.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
400 mg b.i.d. and doubling the dose every two weeks until a maximum of 1600 mg b.i.d. (8 weeks treatment).
Route of Administration:
Oral
ACTIVE MOIETY
